Nectar Lifescience Ltd (NECLIFE) — shareholding pattern, promoter holding, financials and share price
About Nectar Lifescience Ltd (NECLIFE)
Nectar Lifescience Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as NECLIFE and on the BSE under scrip code 532649. Its ISIN is INE023H01027.
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations [1]
Nectar Lifesciences Ltd is a leading global pharmaceutical company specializing in the manufacturing of Cephalosporin APIs and formulations. It holds a strong market position due to its integrated manufacturing ecosystem, allowing it to excel in advanced pharmaceutical production and distribution capabilities.
The company's recent performance highlights a significant increase in PAT by 399.36% YoY in Q3 FY25, driven by operational efficiencies and process improvements.
Listed peers in Pharmaceuticals: Syschem (India) Ltd, Accretion Nutraveda Ltd, Kerala Ayurveda Ltd, Coral Laboratories Ltd, Brooks Laboratories Ltd, Oxygenta Pharmaceutical Ltd.
Valuation & Returns
28 Jul 2026At ₹10.2 a share on 28 Jul 2026, Nectar Lifescience Ltd (NECLIFE) was valued at a price-to-earnings ratio of -0.69x against an industry P/E of 37.21x and a price-to-book of 0.21x on a book value of ₹49.22 per share as of Mar 2025. Solomo computes return on equity of -3.47% and return on capital employed of -2.78% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -0.69x
- Industry P/E
- 37.21x
- P/B
- 0.21x
- EPS (TTM)
- ₹-1.71
- Book value / share
- ₹49.22
- ROE
- -3.47%
- ROCE
- -2.78%
- ROA
- -1.62%
- Debt / equity
- 0.61x
- Dividend yield
- 0%
- 52-week range
- ₹9.2 – ₹22.49
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Nectar Lifescience Ltd (NECLIFE) reported revenue of ₹2 crore, net profit of ₹-293 crore and earnings per share of ₹-15.08. That compares with revenue of ₹1,664 crore and net profit of ₹-114 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1 crore and net profit ₹-68 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,665 | 1,520 | 1,682 | 1,664 | 2 |
| Net profit (₹ cr) | 25 | -24 | 5 | -114 | -293 |
| EPS (₹) | 1.12 | -1.08 | 0.22 | -5.07 | -15.08 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 0.69% | -6.28% | -0.29% | -0.84% |
| Stock price CAGR | -12% | -22% | -26% | -39% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 51.84% of Nectar Lifescience Ltd (NECLIFE) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.5% and domestic institutional investors (DII) hold 3.74%. Market capitalisation was ₹198 crore on 28 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2005.
Largest disclosed public shareholders in Jun 2026: RAJASTHAN GLOBAL SECURITIES PRIVATE LIMITED 3.73%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 51.84% | - | 0.5% | 3.74% | 48.16% |
| Mar 2026 | 51.84% | - | 0.6% | 4.01% | 48.16% |
| Dec 2025 | 51.84% | - | 0.58% | 3.54% | 48.16% |
| Sep 2025 | 44.91% | 98.8% | 0.62% | 0.09% | 55.09% |
| Jun 2025 | 44.53% | 99.6% | 0.81% | 0.19% | 55.47% |
| Mar 2025 | 44.53% | 99.6% | 1.65% | 0.16% | 55.47% |
| Dec 2024 | 44.53% | 99.6% | 0.73% | - | 55.47% |
| Sep 2024 | 55.8% | 100% | 3.24% | - | 44.2% |